Initiate enrollment in the second dose cohort of the AMT-191 study
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 27 Feb 2025
- Due
- 30 Jun 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The Company expects to initiate enrollment in the second dose cohort in the second quarter of 2025”
What we found
Evidence strength A What the grades mean
uniQure initiated enrollment in the AMT-191 second dose cohort in Q1 2025, ahead of the Q2 2025 deadline stated in the February 27, 2025 announcement.
-
A uniQure N.V. - Form 10-K - FY2025
“During 2025, we enrolled three patients in a second, lower dose cohort in our Phase I/II clinical trial of AMT-191 for the treatment of Fabry disease, as well as enrolled four patients in a third cohort.” ✓ confirmed on the page
-
B uniQure Announces 2024 Financial Results and Highlights Recent Company Progress
“The Company initiated enrollment in the second dose cohort in the first quarter of 2025 and expects to present initial data from the study in the first half of 2026.”
Checked 7 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +457 days
- 2 versions
-
Version 1 · original · stated 27 Feb 2025
Deadline 30 Jun 2025 (“in the second quarter of 2025”) · wording expected
-
Version 2 · stated 29 Jul 2026
Deadline 30 Sep 2026 (“third quarter of 2026”) · wording expected
“The Company expects to complete enrollment in the second dose cohort in the Phase I/IIa study in the third quarter of 2026.”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- Clinical trial enrollment
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you uniQure N.V.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-QURE-001903 · Corrections policy